```html

Quinine‑Associated Cardiac Arrhythmia

Overview

Quinine is an alkaloid derived from the bark of the cinchona tree. Historically it has been used to treat malaria and, more recently, as a component of over‑the‑counter “nighttime” or “leg‑cramp” medications. While quinine is generally safe at low, therapeutic doses, it can affect the heart’s electrical system, leading to cardiac arrhythmias—abnormal heart rhythms that may be harmless or life‑threatening.

Who it affects: Anyone who ingests quinine—whether prescribed for malaria, taken as a supplement for nocturnal leg cramps, or consumed inadvertently in herbal products—can develop an arrhythmia. The risk is higher in adults over 60, patients with pre‑existing heart disease, and those taking other QT‑prolonging drugs.

Prevalence: Serious quinine‑related arrhythmias are rare. A review of the U.S. FDA’s Adverse Event Reporting System (FAERS) identified ≈1,200 reports of cardiac events linked to quinine from 2000‑2020, representing <0.1% of all quinine exposures. However, the true incidence may be under‑reported because many mild arrhythmias go unnoticed.

Understanding the link between quinine and heart rhythm disturbances helps patients and clinicians recognize warning signs early and take appropriate action.

Symptoms

Arrhythmias may be silent or cause a range of sensations. When quinine is the trigger, symptoms often appear within hours to a few days after the dose.

• Palpitations – sensation of a “fluttering,” “skipping,” or “rapid” heartbeat.
• Dizziness or Light‑headedness – caused by reduced cardiac output.
• Syncope (fainting) – sudden loss of consciousness, especially with sustained ventricular tachycardia.
• Chest discomfort or pain – may mimic angina; often a warning of ischemia secondary to a rapid rate.
• Shortness of breath (dyspnea) – particularly on exertion.
• Fatigue or weakness – resulting from inefficiency of the heart’s pumping action.
• Blurred vision or “floaters” – rare, but reported with severe QT prolongation.
• Seizures or sudden cardiac arrest – extremely rare but possible in the setting of torsades de pointes, a type of polymorphic ventricular tachycardia.

If any of these symptoms appear after taking quinine, seek medical evaluation promptly.

Causes and Risk Factors

How quinine leads to arrhythmia

Quinine blocks the cardiac potassium channel (hERG, I<sub>Kr</sub>) responsible for repolarization of the ventricular action potential. Inhibition lengthens the QT interval on an electrocardiogram (ECG). A prolonged QT creates a substrate for early after‑depolarizations, which can trigger torsades de pointes or other ventricular arrhythmias.

Key risk factors

• High quinine dose – >200 mg three times daily (common in night‑cramp products) markedly increases QT prolongation risk.
• Concomitant QT‑prolonging medications – e.g., macrolide antibiotics, fluoroquinolones, certain antipsychotics, and antiarrhythmics.
• Electrolyte disturbances – low potassium (hypokalemia), magnesium (hypomagnesemia), or calcium (hypocalcemia) amplify QT effects.
• Pre‑existing cardiac disease – heart failure, prior myocardial infarction, congenital long‑QT syndrome.
• Renal or hepatic impairment – reduced drug clearance leads to higher plasma concentrations.
• Age > 60 years – age‑related decline in drug metabolism and higher prevalence of comorbidities.
• Female sex – women generally have longer baseline QT intervals and are more susceptible to drug‑induced QT prolongation.

Diagnosis

Clinical evaluation

Diagnosis starts with a thorough history (quinine exposure, timing of symptoms, other medications, past cardiac history) and physical examination (heart rate, blood pressure, signs of heart failure).

Electrocardiogram (ECG)

• Baseline 12‑lead ECG to measure QT interval. A QTc (corrected QT) > 450 ms in men or > 470 ms in women is considered prolonged.
• Serial ECGs after quinine administration can document dynamic changes.

Laboratory tests

• Serum electrolytes – potassium, magnesium, calcium.
• Renal and hepatic function panels – eGFR, AST/ALT.
• Quinine serum level – rarely needed, but useful in severe toxicity.

Advanced cardiac testing (if indicated)

• Holter monitor or event recorder – captures intermittent arrhythmias over 24‑48 hours or longer.
• Electrophysiology (EP) study – reserved for refractory cases or when underlying channelopathy is suspected.
• Echocardiography – assesses cardiac structure and function to rule out structural heart disease.

Diagnostic criteria

A diagnosis of quinine‑associated arrhythmia is made when:

1. Temporal relationship between quinine ingestion and arrhythmic symptoms;
2. ECG demonstrates QT prolongation or another arrhythmic pattern not explained by another cause;
3. Symptoms improve after discontinuation (de‑challenge) or recur with re‑exposure (re‑challenge, rarely performed for safety).

Treatment Options

Immediate management

• Discontinue quinine – the most critical first step.
• Correct electrolytes – intravenous magnesium sulfate (2 g over 15 min) is first‑line for torsades de pointes; potassium replacement to keep serum K⁺ ≥ 4.0 mmol/L.
• Monitoring – continuous cardiac telemetry for at least 24 hours after drug cessation.

Pharmacologic therapy

• Beta‑blockers (e.g., metoprolol) – slow heart rate and reduce ectopic activity for supraventricular tachyarrhythmias.
• Class Ia antiarrhythmics (e.g., procainamide) are usually avoided because they also prolong QT.
• Isoproterenol infusion – may be used in refractory torsades to increase heart rate and shorten QT.

Electrical interventions

• Defibrillation – immediate unsynchronised shock for ventricular fibrillation or pulseless torsades.
• Overdrive pacing – temporary transvenous pacing at 90–110 bpm can suppress torsades by shortening repolarisation.

Long‑term considerations

• In patients with persistent QT prolongation after quinine clearance, consider referral to an electrophysiologist for possible implantable cardioverter‑defibrillator (ICD) evaluation.
• Educate patients to avoid future quinine exposure and other QT‑prolonging agents.

Living with Quinine‑Associated Cardiac Arrhythmia

Medication review

Ask every prescriber to check for QT‑prolonging potential. Maintain an up‑to‑date medication list, including over‑the‑counter drugs, supplements, and herbal products.

Heart‑healthy lifestyle

• Follow a low‑sodium, high‑potassium diet (e.g., fruits, vegetables, legumes) unless contraindicated.
• Stay hydrated; dehydration can worsen electrolyte imbalances.
• Engage in regular aerobic activity (150 min/week) as tolerated—avoid extreme exertion if you experience palpitations.
• Limit alcohol and avoid recreational drugs such as cocaine or methamphetamine, which can provoke arrhythmias.

Self‑monitoring

• Know your resting heart rate and baseline pulse; report any sudden increase > 20 bpm.
• Consider a personal ECG device or smartphone‑linked recorder if you have intermittent symptoms.
• Maintain a symptom diary: date, time, dose of any new medication, and description of palpitations or dizziness.

Follow‑up care

Schedule cardiology follow‑up within 1–2 weeks after the acute episode, and repeat ECGs at 1 month and 3 months to ensure QT normalization.

Prevention

• Avoid quinine for leg cramps – FDA recommends against using quinine for this purpose because the risk outweighs benefit.
• Screen before prescribing quinine – obtain baseline ECG in patients > 60 y, with known heart disease, or on other QT‑prolonging agents.
• Correct electrolytes proactively – especially in patients with chronic diuretic use.
• Educate at‑risk groups – older adults, women, and those with renal disease should be counseled on the signs of arrhythmia.
• Use the lowest effective quinine dose for the shortest duration when treatment of malaria is unavoidable.

Complications

If untreated or unrecognized, quinine‑associated arrhythmias can lead to serious outcomes:

• Syncope and falls – especially hazardous in the elderly.
• Heart failure – due to tachycardia‑induced cardiomyopathy.
• Stroke – from atrial fibrillation or sustained rapid ventricular rates decreasing cardiac output.
• Sudden cardiac death – most often from torsades de pointes progressing to ventricular fibrillation.

When to Seek Emergency Care

---

Sources: Mayo Clinic. “Quinine (Oral Route).” 2023; CDC. “Drug-Induced QT Prolongation.” 2022; NIH National Heart, Lung, & Blood Institute. “Long QT Syndrome.” 2021; FDA. “Quinine-Containing Products: Safety Communication.” 2020; Cleveland Clinic. “Torsades de Pointes.” 2022; JAMA Cardiology. “Drug‑Induced QT Prolongation and Ventricular Arrhythmias.” 2021.

```